A Phase 3 interventional study of insulin degludec and insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 40 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-02-10.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 23rd largest by enrollment, is one of 8 that started in 2013, is one of 49 in phase 3, and was the 36th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 8 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 458 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 107th largest by enrollment of the 428 interventional ones that give a count, is one of 33 that started in 2013, is one of 187 in phase 3, and was the 346th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia. The aim of the trial is to investigate the efficacy and safety of flexible versus fixed dosing and simple versus stepwise titration with OD insulin degludec in inadequately treated subjects with type 2 diabetes.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 458 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec
Drug: insulin degludec
Drug: insulin degludec
Drug: insulin degludec
Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.
Change From Baseline in HbA1c (%) Glycosylated Haemoglobin)
Changes from baseline in HbA1c values over time period of Week 0-26 were evaluated by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise)
Time frame: Week 0, week 26
Change From Baseline in Fasting Plasma Glucose (FPG)
Changes from baseline in FPG values over the time period of Week 0-26 were evaluated by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise).
Time frame: Week 0, week 26
Responder for HbA1c (%) Based on Central Laboratory Assessment: HbA1c Below 7.0% at End of Trial
The number of subjects who achieved the pre-defined HbA1c target (\<7.0%) after 26 weeks of treatment was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise).
Time frame: After 26 weeks of treatment
Incidence of Treatment Emergent Adverse Events (TEAEs)
The incidences of treatment emergent adverse events (TEAEs) over the time period of Week 0-26 were recorded by dosing regimen (flexible vs. fixed dosing); and by titration algorithm (simple vs stepwise).
Time frame: Weeks 0-26
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes (Defined as Severe Hypoglycaemia and/or a Measured Plasma Glucose (PG) Less Than 3.1 mmol/L (Less Than 56 mg/dL))
The confirmed hypoglycaemic episodes (defined as severe hypoglycaemia and/or a measured plasma glucose (PG) less than 3.1 mmol/L \[less than 56 mg/dL\]) over the time period of Week 0-26 was recorded by dosing regimen (flexible vs. fixed dosing); and by titration algorithm (simple vs stepwise).
Time frame: Weeks 0-26
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association (ADA) Definition
Number of treatment emergent hypoglycaemic episodes according to the ADA definition (classified as severe hypoglycaemia, documented hypoglycaemia, asymptomatic hypoglycaemia, probable symptomatic hypoglycaemia, relative hypoglycaemia) over the time period of Week 0-26 was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise).
Time frame: Weeks 0-26
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes in the Maintenance Period
The number of treatment mergent confirmed hypoglycaemic episodes in the maintenance period from Week 16 to end of trial (week 27) was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs. stepwise). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L.
Time frame: From Week 16 to end of trial (week 27)
Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes
The number of treatment emergent nocturnal (00:01-05:59 am) confirmed hypoglycaemic episodes over the time period of Week 0-26 was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.
Time frame: Weeks 0-26
Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes in the Maintenance Period
The number of treatment emergent nocturnal (00:01-05:59 am) confirmed hypoglycaemic episodes in the maintenance period from 16 weeks to end of trial (week 27) was recorded by dosing regimen (flexible vs. fixed dosing); and by titration algorithm (simple vs stepwise). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.
Time frame: From week 16 to end of trial (week 27)
The trial was conducted at 39 sites in Japan.
| Milestone | IDeg OD Fixed Dosing and Simple Titration (Arm A) | IDeg OD Fixed Dosing and Stepwise Titration (Arm B) | IDeg OD Flexible Dosing and Simple Titration (Arm C) | IDeg OD Flexible Dosing and Stepwise Titration (Arm D) |
|---|---|---|---|---|
| Started | 114 | 115 | 115 | 114 |
| Completed | 113 | 113 | 114 | 108 |
| Not completed | 1 | 2 | 1 | 6 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal criteria | 1 | 2 | 1 | 5 |
Changes from baseline in HbA1c values over time period of Week 0-26 were evaluated by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise)
| Percent (%) glycosylated haemoglobin | IDeg OD Flexible (Arm C+Arm D) | IDeg OD Fixed (Arm A+Arm B) | IDeg OD Simple (Arm A+Arm C) | IDeg OD Stepwise (Arm B+Arm D) |
|---|---|---|---|---|
| Change From Baseline in HbA1c (%) Glycosylated Haemoglobin) | -0.54 ± 0.76 | -0.62 ± 0.75 | -0.57 ± 0.72 | -0.59 ± 0.80 |
Changes from baseline in FPG values over the time period of Week 0-26 were evaluated by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise).
| mg/dL | IDeg OD Flexible (Arm C+Arm D) | IDeg OD Fixed (Arm A+Arm B) | IDeg OD Simple (Arm A+Arm C) | IDeg OD Stepwise (Arm B+Arm D) |
|---|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) | -28.8 ± 39.0 | -25.4 ± 40.2 | -27.0 ± 35.3 | -27.2 ± 43.6 |
The number of subjects who achieved the pre-defined HbA1c target (\<7.0%) after 26 weeks of treatment was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise).
| Subjects | IDeg OD Flexible (Arm C+Arm D) | IDeg OD Fixed (Arm A+Arm B) | IDeg OD Simple (Arm A+Arm C) | IDeg OD Stepwise (Arm B+Arm D) |
|---|---|---|---|---|
| Responder for HbA1c (%) Based on Central Laboratory Assessment: HbA1c Below 7.0% at End of Trial | 90 | 95 | 91 | 94 |
The incidences of treatment emergent adverse events (TEAEs) over the time period of Week 0-26 were recorded by dosing regimen (flexible vs. fixed dosing); and by titration algorithm (simple vs stepwise).
| events | IDeg OD Flexible (Arm C+Arm D) | IDeg OD Fixed (Arm A+Arm B) | IDeg OD Simple (Arm A+Arm C) | IDeg OD Stepwise (Arm B+Arm D) |
|---|---|---|---|---|
| Incidence of Treatment Emergent Adverse Events (TEAEs) | 150 | 154 | 138 | 166 |
The confirmed hypoglycaemic episodes (defined as severe hypoglycaemia and/or a measured plasma glucose (PG) less than 3.1 mmol/L \[less than 56 mg/dL\]) over the time period of Week 0-26 was recorded by dosing regimen (flexible vs. fixed dosing); and by titration algorithm (simple vs stepwise).
| episodes | IDeg OD Flexible (Arm C+Arm D) | IDeg OD Fixed (Arm A+Arm B) | IDeg OD Simple (Arm A+Arm C) | IDeg OD Stepwise (Arm B+Arm D) |
|---|---|---|---|---|
| Number of Treatment Emergent Confirmed Hypoglycaemic Episodes (Defined as Severe Hypoglycaemia and/or a Measured Plasma Glucose (PG) Less Than 3.1 mmol/L (Less Than 56 mg/dL)) | 476 | 371 | 469 | 378 |
Number of treatment emergent hypoglycaemic episodes according to the ADA definition (classified as severe hypoglycaemia, documented hypoglycaemia, asymptomatic hypoglycaemia, probable symptomatic hypoglycaemia, relative hypoglycaemia) over the time period of Week 0-26 was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise).
| episodes | IDeg OD Flexible (Arm C+Arm D) | IDeg OD Fixed (Arm A+Arm B) | IDeg OD Simple (Arm A+Arm C) | IDeg OD Stepwise (Arm B+Arm D) |
|---|---|---|---|---|
| ADA Events Overall | 3053 | 2736 | 3089 | 2700 |
| Severe | 0 | 1 | 1 | 0 |
| Documented symptomatic | 1262 | 1141 | 1293 | 1110 |
| Asymptomatic | 1523 | 1283 | 1505 | 1301 |
| Probable symptomatic | 87 | 131 | 103 | 115 |
| Relative | 181 | 180 | 187 | 174 |
The number of treatment mergent confirmed hypoglycaemic episodes in the maintenance period from Week 16 to end of trial (week 27) was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs. stepwise). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L.
| episodes | IDeg OD Flexible (Arm C+Arm D) | IDeg OD Fixed (Arm A+Arm B) | IDeg OD Simple (Arm A+Arm C) | IDeg OD Stepwise (Arm B+Arm D) |
|---|---|---|---|---|
| Number of Treatment Emergent Confirmed Hypoglycaemic Episodes in the Maintenance Period | 227 | 192 | 241 | 178 |
The number of treatment emergent nocturnal (00:01-05:59 am) confirmed hypoglycaemic episodes over the time period of Week 0-26 was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.
| episodes | IDeg OD Flexible (Arm C+Arm D) | IDeg OD Fixed (Arm A+Arm B) | IDeg OD Simple (Arm A+Arm C) | IDeg OD Stepwise (Arm B+Arm D) |
|---|---|---|---|---|
| Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes | 77 | 58 | 80 | 55 |
The number of treatment emergent nocturnal (00:01-05:59 am) confirmed hypoglycaemic episodes in the maintenance period from 16 weeks to end of trial (week 27) was recorded by dosing regimen (flexible vs. fixed dosing); and by titration algorithm (simple vs stepwise). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.
| episodes | IDeg OD Flexible (Arm C+Arm D) | IDeg OD Fixed (Arm A+Arm B) | IDeg OD Simple (Arm A+Arm C) | IDeg OD Stepwise (Arm B+Arm D) |
|---|---|---|---|---|
| Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes in the Maintenance Period | 34 | 23 | 40 | 17 |
Collected over This included events from the first trial related activity after the subject had signed the informed consent and until the end of the follow-up period (Week 27).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDeg OD Flexible (Arm C+Arm D) | — | 8/229 (3.5%) | 79/229 (34.5%) |
| IDeg OD Fixed (Arm A+Arm B) | — | 6/229 (2.6%) | 82/229 (35.8%) |
| IDeg OD Simple (Arm A+Arm C) | — | 7/229 (3.1%) | 78/229 (34.1%) |
| IDeg OD Stepwise (Arm B+Arm D) | — | 7/229 (3.1%) | 83/229 (36.2%) |
| Event | IDeg OD Flexible (Arm C+Arm D) | IDeg OD Fixed (Arm A+Arm B) | IDeg OD Simple (Arm A+Arm C) | IDeg OD Stepwise (Arm B+Arm D) |
|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 0/229 | 2/229 | 1/229 | 1/229 |
| Acute myocardial infarctionCardiac disorders | 0/229 | 1/229 | 0/229 | 1/229 |
| Arteriosclerosis coronary arteryCardiac disorders | 1/229 | 0/229 | 0/229 | 1/229 |
| Left ventricular hypertrophyCardiac disorders | 1/229 | 0/229 | 0/229 | 1/229 |
| EnterocolitisGastrointestinal disorders | 1/229 | 0/229 | 1/229 | 0/229 |
| Non-cardiac chest painGeneral disorders | 0/229 | 1/229 | 1/229 | 0/229 |
| CellulitisInfections and infestations | 1/229 | 0/229 | 1/229 | 0/229 |
| PneumoniaInfections and infestations | 0/229 | 1/229 | 1/229 | 0/229 |
| Joint dislocationInjury, poisoning and procedural complications | 1/229 | 0/229 | 1/229 | 0/229 |
| Upper limb fractureInjury, poisoning and procedural complications | 0/229 | 1/229 | 1/229 | 0/229 |
| Event | IDeg OD Flexible (Arm C+Arm D) | IDeg OD Fixed (Arm A+Arm B) | IDeg OD Simple (Arm A+Arm C) | IDeg OD Stepwise (Arm B+Arm D) |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 67/229 | 69/229 | 68/229 | 68/229 |
| Diabetic retinopathyEye disorders | 24/229 | 20/229 | 18/229 | 26/229 |
The full analysis set (FAS) included all randomised subjects. The statistical evaluation of the FAS followed the intention-to-treat (ITT) principle and subjects contributed to the evaluation "as randomised".
| Age, Continuous(years) | IDeg OD Fixed Dosing and Simple Titration (Arm A) | IDeg OD Fixed Dosing and Stepwise Titration (Arm B) | IDeg OD Flexible Dosing and Simple Titration (Arm C) | IDeg OD Flexible Dosing and Stepwise Titration (Arm D) | Total |
|---|---|---|---|---|---|
| Mean | 60.4 ± 10.6 | 60.7 ± 10.5 | 60.0 ± 10.8 | 60.2 ± 10.8 | 60.3 ± 10.7 |
| Gender(Participants) | IDeg OD Fixed Dosing and Simple Titration (Arm A) | IDeg OD Fixed Dosing and Stepwise Titration (Arm B) | IDeg OD Flexible Dosing and Simple Titration (Arm C) | IDeg OD Flexible Dosing and Stepwise Titration (Arm D) | Total |
|---|---|---|---|---|---|
| Female | 41 | 41 | 50 | 34 | 166 |
| Male | 73 | 74 | 65 | 80 | 292 |
| Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | IDeg OD Fixed Dosing and Simple Titration (Arm A) | IDeg OD Fixed Dosing and Stepwise Titration (Arm B) | IDeg OD Flexible Dosing and Simple Titration (Arm C) | IDeg OD Flexible Dosing and Stepwise Titration (Arm D) | Total |
|---|---|---|---|---|---|
| Mean | 7.8 ± 0.6 | 7.8 ± 0.6 | 7.8 ± 0.5 | 7.8 ± 0.6 | 7.8 ± 0.6 |
| Fasting plasma glucose (FPG)(mg/dL) | IDeg OD Fixed Dosing and Simple Titration (Arm A) | IDeg OD Fixed Dosing and Stepwise Titration (Arm B) | IDeg OD Flexible Dosing and Simple Titration (Arm C) | IDeg OD Flexible Dosing and Stepwise Titration (Arm D) | Total |
|---|---|---|---|---|---|
| Mean | 129.8 ± 30.0 | 136.0 ± 38.1 | 131.8 ± 33.5 | 134.5 ± 39.6 | 133.0 ± 35.5 |
The record gives a start of Jun 2013, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin degludec